It has been a terrible year for Sanofi-Aventis’s controversial heart drug Multaq. So much controversy has surrounded the drug ever since its side effects like liver failure and actually worsening patients’ heart conditions started making headlines. These side effects have caused France to refuse to pay for the drug to be used by its citizens.

France recently made the announcement that it would no longer be paying reimbursements to patients using Multaq in the country because the country’s health officials say the drug doesn’t give proper medical help. What this means is that France is killing Multaq use insofar as the state-run health care market is concerned. France’s decision is based on results of a clinical trial that Sanofi halted after patients started dying while taking the drug as a treatment for permanent atrial fibrillation (AF). The PALLAS study was meant to test Multaq’s ability to treat permanent AF since it was already approved to treat temporary AF. The problem with the test was that it worsened many patients’ heart conditions instead of making them better.

And as if that wasn’t bad enough, studies have also shown that Multaq causes some patients to suffer from liver failure as well. Often times, the patients’ liver failure was so extreme, they had to get a liver transplant. This is why France’s most recent announcement doesn’t come as a shock to anyone. Back in September, the European Medical Association (EMA) announced that it was restricting Multaq use to patients whose conditions weren’t responding to other treatments. From all of this, many people are already calling for the drug to be recalled, but so far it remains on the market in the U.S.

If you or a loved one have developed liver failure or a worsening heart problem after taking Multaq, contact attorney Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.